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Isochrysis is commercially available marine 
algae used for animal feed, human nutrient 
supplements, and biodiesel. The Isochrysis species 
is one of five genera of haptophytes that produces 
unique, long-chain lipids known as alkenones that 
are promising new ingredients for green cosmetics, 
personal care products and pharmaceutical delivery. 
However, there is a lack of toxicity data for alkenones 
in animals, thus limiting their use in humans. In this 
study, we performed acute oral, acute dermal, and 
repeated 28-day dermal toxicity studies, using female 
SAS Sprague Dawley Rats. Our behavioral studies 
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indicated that the specific alkenones had no overt 
behavioural effects at oral doses up to 4000 mg/kg. 
In the acute and chronic dermal toxicity studies, the 
alkenones produced less irritation and did not 
significantly damage the skin based on the Draize 
skin reaction scale and trans-epidermal water loss 
readings compared to the positive control, 1% 
sodium lauryl sulfate. Overall, our results indicated 
that alkenones are safe in Sprague Dawley rats, 
suggesting that they could be used for both oral and 
dermal formulations, although additional studies will 
be required. 
2. INTRODUCTION 
Due to the increasing shift in consumer 
demand for products with organic ingredients, 
personal care industries are expanding their products 
to include natural, green, and sustainable ingredients 
(1, 2). Natural ingredients, such as mushrooms, 
wheat, green tea, bacteria, yeast, marine algae, and 
certain microorganisms (3-5) have been shown to 
promote skin elasticity, activation of skin cell renewal 
and metabolism, and have anti-inflammatory efficacy 
(3, 4, 6, 7). The extracts of bioactive substances 
derived from these natural ingredients have been 
reported to have anti-inflammatory and antioxidant 
efficacy, as well as inhibiting NF-κB-meditated gene 
expression and a low likelihood of producing 
significant toxicity (8-10). For example, extracts from 
microalgae genera such as Arthrospira, Anacystis, 
Chlorella, Dunaliella, Halymenia, Nannochloris, and 
Spirulina, enhance collagen synthesis, preventing 
wrinkle formation, and contain amino acids and 
carotenoids that provide protection against sun 
damage (11). Interestingly, no independent studies 
have been performed or reported toxicity/safety for 
many of these marine extracts, perhaps due to lack 
of adverse clinical reports among consumers. 
Marine microalgae-derived extracts from 
harvested seaweed are used as animal feed, 
wastewater treatment, biofuels, pharmaceuticals 
(11), and for nutraceutical and personal care 
applications (12). Because marine microalgae must 
adapt to new environments when exposed to 
extreme conditions (13), they typically produce 
diverse secondary, biologically active metabolites 
that are not present in terrestrial plants (14). There 
are an estimated 200,000 to several million species 
of microalgae, (11) and their unique metabolites 
could be of importance in the development of drug 
delivery or personal care formulations. Some of these 
compounds could be incorporated into drug/personal 
care formulations, including mycosporine-like amino 
acids, glucosyl glycerols, polysaccharides, sulfated 
polysaccharides, polyphenols, and lipids, which can 
be further biotransformed into alkenones. Alkenones 
are long-chain lipids, consisting of 35-41 carbons 
(15), with a high melting temperature (~70 °C), (16) 
thereby making them potential compounds for use in 
pharmaceuticals formulations when developing 
topically delivered drugs. Pavlova salina and 
Isochrysis galbana are the best-known species of the 
phylum Haptophyta and are produced globally (11). 
The Isochrysis sp. is a non-toxic food source for 
cultivated marine animals (17) as it produces 
essential polyunsaturated fatty acids, such as 
eicosapentaenoic acid and docosahexaenoic acid for 
the growth and development of fish larvae (18). 
Four strains of Isochrysis sp. have been 
reported to produce alkenones (19). Pure alkenones 
can be isolated from Isochrysis using a 5-step 
process (15). Alkenones have historically been used 
as reliable palaeothermometers (20). However, more 
recently alkenones have been investigated as a 
source of biofuel (21) and as an ingredient in topical 
formulas. For example, the alkenones physical 
characteristics were previously reported (16) to be 
compatible with commonly used waxes (e.g., 
microcrystalline wax and ozokerite) in lipstick and lip 
balm products. Furthermore, the alkenones simplified 
molecular-input line-entry system (SMILES) were 
entered into Formulating for Efficacy™ (ACT 
Solutions Corp, Kirkwood, DE, USA), to generate 
Hansen Solubility Parameters (16). The Formulating 
for Efficacy™ was used to calculate the molar volume 
(MVol), Ingredient-Skin Gap value (ISG), LogK and 
Solubility in Skin (SolS). The smaller the ISG value 
is, the more compatible that ingredient is with the 
outer layer of the epidermis, the stratum corneum, 
and the greater tendency for that ingredient to 
penetrate the skin. Similarly, the smaller the MVol 
value, the greater likelihood that ingredient will 
penetrate the skin. The alkenones had high MVol and 
ISG values and low SolS value of 0.3 which is ideal 
for topical skin applications. However, the toxicity of 
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the alkenones has not been assessed in animals, 
which is essential information for these applications. 
In this study, female SAS Sprague Dawley (SD) rats 
were given p.o. alkenones acutely and repeatedly 
and the major organs were removed and analyzed for 
damage. Furthermore, blood chemistry protein levels 
were measured in whole blood taken from the rats 
after the oral acute treatment. Finally, we determined 
the effects of an alkenone-containing paste (applied 
once a day for 28 days) on the dorsal skin sites of 
rats. 
3. MATERIALS AND METHODS 
3.1. Test materials 
The marine microalgae Isochrysis was 
purchased from Necton S.A. (Olhão, Portugal). 
Alkenones were isolated, purified and characterized 
from the Isochrysis biomass as previously described 
(15, 22, 23). Briefly, dried Isochrysis was put through 
a Soxhlet extraction process and the resulting extract 
saponified (allowing for separation of fatty acids and 
neutral lipids), and finally alkenones were isolated 
and purified from the neutral lipids by crystallization 
(15). Sodium chloride (0.9%) was purchased from 
BioVision Incorporated (Milpitas, CA, USA). The 
following items were received as gifts: natural 
glycerin, (Spectrum, New Brunswick, NJ, USA); 
sodium lauryl sulfate (SLS) (PCCA, Houston Texas, 
USA); hydroxypropylmethylcellulose (HPMC) 
(Spectrum Chemical, Gardena, CA, USA). All 
ingredients were of pharmaceutical grade. 
Vehicles used for the alkenones and other 
treatments are later described 3.3.1 and 3.8 in this 
article. 
3.2. Experimental animals 
Seven-week-old female SAS Sprague 
Dawley (SD) rats (180-200 grams) were obtained 
from Charles River (Wilmington MA) and used for the 
acute oral, acute dermal, and repeated dermal 
toxicity tests. Twelve rats were used for the acute oral 
toxicity test, whereas ten rats were used for the acute 
dermal toxicity and ten rats for the repeated dose 28-
day dermal toxicity. The toxicity tests were performed 
according to the Organization for Economic 
Cooperation and Development (24) test guideline, 
i.e., OECD Guideline 423 for the acute oral toxicity 
test (25) and OECD Guideline 404 for the acute 
dermal toxicity test (26-28), with slight modifications. 
The injection volume (4mL/kg) was adjusted 
depending on the body weight of the rat (29). The 
female rats were nulliparous and non-pregnant. The 
SD rats were given standard rat pellets (Envigo 
Teklad) and reverse osmosis water ad libitum. They 
were acclimatized to the laboratory conditions for 7 
days before the experiments. The rats were housed 
in groups, depending on the weight of the animal, in 
accordance with IACUC guidelines (three to four rats 
for acute oral toxicity and two to three rats for acute 
and repeated dermal toxicity). The animals were 
housed under a 12-hour light/dark cycle, at 
temperatures of 23±2 degree Celsius) and a humidity 
of 55±5%. The animal protocol for this study was 
approved by the Institutional Animal Care and Use 
Committee of The University of Toledo and was in 
accordance with all National Institutes of Health 
guidelines (No. 8023, revised 1978) for animal 
research, including the Guide for the Care and Use 
of Laboratory Animals (Institute of Laboratory Animal 
Resources, Commission on Life Sciences, 1996). 
3.3. Study design 
To assess the alkenones toxicity in the rats, 
three independent toxicity studies were performed 
i.e. oral exposure of alkenones up to 24 hours, one-
time dermal exposure for 14 days, and repeated 6-
hour dermal exposure for 28 days. The study design 
is presented in the form of cartoon schematic 
diagram (Figure 1a). Briefly, the doses used were 
modified from the OECD Guideline 420 for the oral 
administration study and the OECD Guideline 434 
dosages were used to determine the dose of acute 
dermal exposure and repeated exposure. For oral 
exposure, the animals were randomly divided 
between two groups with N = 6 vehicle and vehicle 
containing the alkenones. Further, as shown in 
Figure 1b acute dermal exposure of alkenones were 
performed in 2 standalone studies, with N = 5 SD rats 
for each study. The first study used the highest 
possible test dose of alkenones that could be applied 
in 6.25 cm2, i.e., that was compared to the nearby 
exposures of vehicle, positive control (1% SLS) and 
negative control (saline). We repeated the same  
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Figure 1. (A) Experimental design showing duration of administration of alkenones for three different studies in SAS Sprague Dawley rats. (B) 
Experimental design showing the site (6.25 cm2) of acute dermal applications of different treatments in two stand-alone studies. (C) 
Experimental design showing the site (6.25 cm2) of repeat dermal applications of different treatments in two stand-alone studies. 
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procedures in Study 2 with N = 5 SD rats, but instead 
of using negative control (which was non-toxic in first 
study), we applied an additional 750 mg/kg dose 
adjacent to high dose for two reasons: (a) to 
determine the effect of alkenones on the dermis on a 
large surface area on the same rat, i.e., a total of 
2250 mg/kg exposure in 12.50 cm2 area; (b) to 
determine if there would be any effects from different 
concentrations of the alkenones with the vehicle. 
Later, as shown in Figure 1c, the first repeated 
exposure study would use a high dose of 1000 mg/kg 
alkenones that could be applied in 6.25 cm2 and 
compared to the nearby exposures of vehicle, 1% 
SLS and saline for 6-hours a day for 28 days. We 
repeated the same procedures in Study 2 with n = 5 
SD rats, but instead of choosing the vehicle and 
saline, we applied two additional doses of 200 and 50 
mg/kg alkenones. This would (a) determine if the 
dermal exposure of the alkenones on a greater 
surface area could be tolerated on the same rat, i.e., 
a total of 1250 mg/kg exposure in an 18.75 cm2 area; 
(b) determine if there would be any effects of the 
different concentrations of the alkenones with the 
vehicle following daily exposure. 
3.4. Suspension 
Due to the long chain structure of the 
alkenones, finding a suitable solvent to test it with in vitro 
test methods can be problematic (30, 31). The 
alkenones were not soluble in solvents such as DMSO, 
Tween 80, Tween 20, Sesame seed oil, and Dulbecco’s 
modified Eagle’s medium (DMEM) media. Therefore, 
we used a suspension formulation to administer the 
alkenones to rats using oral gavage. After weighing, the 
alkenones were pulverized using a mortar and pestle, 
and glycerin was added as a wetting agent to form a 
paste. Hydroxypropylmethylcellulose (HPMC) was 
placed in water heated to 80 ºC to yield a 3% w/v 
solution. The HPMC solution was vortexed and allowed 
to cool to room temperature. The 3% w/v of HPMC was 
added to the paste. The resulting suspension was 
poured into a large test tube and withdrawn using an 
oral gavage stainless steel needle (3 inches length and 
ball diameter of 2.25 mm) before dosing the rats. 
3.5. Sub-acute oral gavage of the alkenones 
The alkenones suspension and vehicle 
suspension alone were administered to female rats 
by oral gavage in divided doses of 1 mL/kg body for 
a total of 4000 mg/kg body weight. The starting dose 
of 1000 mg/kg of the alkenones in the suspension 
vehicle and the vehicle itself was used on two 
individual rats (four total) as a starting dose as 
recommended by Whitehead and Stallard (32), with 
modifications. When that dosage did not produce a 
loss of more than 20% body weight, change in 
physical appearance, or change in behavioral pattern 
after 48 hours, two more animals recieved 2000 
mg/kg of the alkenones. After 48 hours, the 2000 
mg/kg dose did not appear to be toxic to the animals. 
Twelve female SD rats were divided into two groups 
(6 rats per group). Group 1, over a period of up to 24-
hours, was given a total of 4000 mg/kg of the 
alkenones derived from Isochrysis sp. that was 
prepared in a suspension of glycerin and 3% HPMC. 
Group 2 received the vehicle only with the same 
dosage. The rats were observed for general 
behavioral changes using the body condition scoring 
scale, based on the following typical signs: failure to 
eat or drink, ruffled fur, runny eyes, respiratory 
distress, abdominal pain (hunched posture), or 
weight loss in excess of 20% (weighed daily). In 
addition, the facial expression of the rats was 
observed and measured based on the Grimace 
Scale, as suggested by Sotocinal et al. (33), for 
changes in position for ears and whiskers, for orbital 
tightening, and nose/cheek flattening. Symptoms of 
toxicity (and mortality) were noted after each divided 
treatment for the first 1 h, followed by observations 
made within 30 minutes of treatment and then at 1, 6, 
12, 24 hours and in parallel, rats in group 2 were 
treated with vehicle (Glycerin and 3% HPMC) to 
establish a comparative negative control group 
according to the guideline (25). All animals were 
observed at least once during the first 30 min in the 
first 24 hours and then again at 4 hours and 24 hours 
following vehicle or alkenones suspension 
administration and then once a day, at approximately 
10 AM, for 14 days, as indicated in the (28) 
guidelines. All behavioral and physical observations, 
including changes in skin, fur, secretions from eyes 
and mucous membrane, and behavioral pattern 
changes such as posture, response to handling, 
motor activity, grip strength and sensory reactivity to 
stimuli were recorded for each rat. Food consumption 
was recorded daily, and the body weight of each 
animal was recorded immediately before the 
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administration of the test substance and daily 
throughout the length of the study. 
3.6. Blood analysis 
At the end of the 14-day observation, 
animals were sacrificed (N = 12) using CO2 
asphyxiation, followed by cardiac puncture. 
Subsequently, 1mL of blood was obtained and 
placed in a 1.3mL K3E Micro tube. Five hundred 
microliters of blood were placed in a test tube 
containing lithium heparin. Subsequently, in whole 
blood samples, the number of RBCs, WBCs, PLTs, 
HGB, and monocytes were determined using a 
VetScan HM5 instrument (Abaxis, Union City, CA, 
USA). 
In a separate lithium heparin test tube with 
collected blood, 120 μL was withdrawn and added to 
the comprehensive diagnostic profile plate (Abaxis, 
Union City, CA, USA) and run in a VetScan 2 device 
(Abaxis, Union City, CA, USA). A panel of functional 
parameters, consisting of albumin, total protein, 
globulin, sodium (Na+), potassium (K+), alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), 
amylase (AMY), total bilirubin (TBIL), bilirubin urea 
nitrogen (BUN), total calcium (CA), phosphorus 
(PHOS), creatinine (CRE), and glucose (GLU), were 
analyzed in whole blood samples using the VetScan 
2 instrument. 
3.7. Histology 
The animals were euthanized at the end 14 
day after sub-acute oral administration using CO2 
asphyxiation, followed by a cardiac puncture for 
collecting blood. Immediately following sacrifice, the 
major organs of each rat (except the brain) were 
evaluated by gross necropsy. Parameters such as 
abnormal growth of lesions, necrosis, changes in 
overall organ size and color were evaluated. The 
brain tissue was not evaluated as alkenones, which 
consist of long carbon chains between 35 and 41 
(21), do not cross the blood-brain barrier. The liver, 
kidneys, spleen, and heart were removed, examined 
for the presence of abnormal lesions, weighed, and 
collected for further histopathological examination. 
The lungs, stomach, intestine, and colon (data not 
shown) were examined as described above and 
weighed, but not collected for histopathological 
examination. Subsequently, the organs were 
immediately fixed in 10% neutral buffered formalin for 
24 hours, then dehydrated in 70% ethanol, and 
embedded in paraffin. The block of embedded tissue 
was cut into 5 µm sections using a microtome 
(Reichert-Jung Biocut 2030 Microtome, Rankin; 
Holly, MI, USA). The resulting tissue sections were 
subjected to a modified protocol from www.aladdin-
e.com (Aladdin, 2018) for haematoxylin and eosin 
(H&E) staining. Images of the tissue sections were 
taken using a VS 120 Virtual Slide Microscope 
(Olympus, Pittsburgh, PA, USA.) The H&E-stained 
images were examined using OlyVIA Ver.2.9 
software. 
3.8. Assessment of the dermal toxicity after 
the sub-acute administration of alkenones 
Twenty-four hours before treatment, fur 
was removed by closely clipping the dorsal area of 
the trunk of the animals according to the guideline 
(26-28). On the treatment day, for Study 1 animals, 
the alkenones were weighed for the administration of 
dermal doses of 750 mg/kg or 1500 mg/kg. The 
doses were based on the OECD guideline 434 fixed 
dose flow chart, where the highest dose that could be 
given was 2000 mg/kg, with 1000 mg/kg as the next 
highest dose. The 2000 mg/kg dose could not be 
formulated as a suspension that could be applied to 
a defined skin site area (approximately 6 cm2). This 
was modified to the highest dosage that could be 
orally administered, which was 1500 mg/kg, with a 
second dose of 750 mg/kg in case of severe irritation 
manifestations during the 24-hour contact exposure 
of the high dose. The alkenones were pulverized in a 
mortar using a pestle. The powder was mixed with a 
fixed amount of glycerin to form a paste-like 
substance. Five rats in Study 1 were exposed to 1500 
mg/kg of alkenones, the positive control, the negative 
control and the vehicle, on four different skin sites of 
each individual animal. Another five rats in the Study 
2 were given the positive control, the vehicle, 1500 
mg/kg, and 750 mg/kg at different skin sites on the 
shaved backs of the rats. The test compound (300 
milligrams of the paste or 300uL of liquid treatment) 
was applied to a small area (approximately 6 cm2) of 
skin and covered with a gauze patch that was held in 
place with non-irritating tape. Other treatments 
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applied at different test sites were a negative control 
(0.9% sodium chloride), a positive control (1% 
sodium lauryl sulfate (SLS: dissolved 0.9% saline 
solution) and glycerin. The rats had ad libitum access 
to standard rat food pellets that were kept in small 
paper cups and water throughout the study. To 
further prevent the rats from removing the covered 
gauze patch, an Elizabethan collar was placed on 
each rat and kept in a separate cage for the 24-hour 
test period. At the end of test period, the covering was 
removed and 1) images of the skin sites were taken; 
2) the reaction of the skin was graded based on the 
Draize skin reaction numerical scale (34) for severity 
of the skin sites from each application and 3) a 
Tewameter reading from each skin site was recorded 
before washing the skin sites with water. Following 
the above tests, the rats were returned to their cages. 
3.9. Assessment of the toxicity after the 
sub-chronic dermal administration of 
alkenones 
The clipping of the fur was done as 
described above. On the treatment day, the animals 
were weighed for the dermal application of 1000, 200, 
and 50 mg/kg of alkenones. These doses were also 
based on the OECD guideline 434 fixed dose flow 
chart. Since we could not reach use the 2000 mg/kg 
dose, we chose to use the other three doses for our 
sub-chronic study. In Study 1 five rats were given the 
positive control, 1000 mg/kg, the negative control and 
the vehicle on four different skin sites. In Study 2 five 
rats were given the positive control, 1000 mg/kg, 200 
mg/kg and 50 mg/kg on four different skin sites. The 
procedure for preparing and applying the treatments, 
the housing of animals, and tests performed after 
treatment were the same as those mentioned for the 
acute dermal administration of the alkenones. 
However, in the sub-chronic studies, the treatment 
time was lowered to a 6-hour period. For the repeated 
dermal toxicity study 6-hour post-application, each 
site was gently wiped with a dry gauze pad to remove 
any remaining paste residue and was allowed to 
breathe for 2-3 minutes before reading with the probe 
occurred. Afterwards, the skin sites were washed 
with autoclaved water for any remaining substances 
on the skin and wiped down again gently with a dry 
gauze pad. This process was done once a day for 28 
consecutive days, after which the animals were 
euthanized, organs dissected and weighed for future 
histological analysis. 
3.10. Determination of skin water loss 
A Tewameter® TM 300, a non-invasive 
device, was used to measure the amount of water 
loss through the skin. The measurement unit for 
reading the rate of loss is known as trans-epidermal 
water loss (TEWL) (35). It has two pairs of sensors in 
the probe to receive corresponding information on 
the temperature and moisture readings of each 
TEWL-value during the complete measurement (36). 
The Tewameter® TM 300 has been accepted for 
measuring TEWL worldwide and has been used in 
both animals (37) and humans (38, 39). The open 
chamber probe was held in the middle of each skin 
site application for 20 seconds before and after 
treatment. The open cylinder chamber probe of the 
Tewameter® TM 300 was held against each skin with 
light pressure for at least 20 seconds to get an 
average reading. TEWL values ranged from 0-10 
(very healthy conditions) to above 30, indicating 
critical skin conditions. If alkenones produce skin 
damage to the skin, then similar to the positive 
control, it should yield high TEWL values. 
3.11. Statistical analysis 
Experimental results were expressed as 
the mean ± standard deviation (SD). Statistical 
analysis of the data was performed using GraphPad 
Prism (Version 7.0, GraphPad Software, La Jolla, 
CA, USA). For the body weight and food consumption 
for the acute oral, dermal, and sub-chronic test, the 
data were not normally distributed and were 
expressed as the modes and analyzed using the 
Mann-Whitney U test. The data from the Vet Scan 
HM5 and VS2 values were all normally distributed 
except for TBIL, BUN, and potassium. Therefore, the 
TBIL, BUN, and potassium data were analyzed using 
the Mann-Whitney U test, whereas the other blood 
chemistry data were analyzed using Welch’s t-test. 
The post-mortem organ weight data were analyzed 
using Welch’s t-test. The Tewameter data for acute 
dermal skin site application was analyzed using a 
mixed effect ANOVA with the treatment and baseline 
measurements as the fixed effect and ID as the 
random effect. For the repeated Tewameter data, a 
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mixed effects model was used with treatment, 
baseline and days (treated as a categorical variable) 
as the fixed effect and ID as the random effect. 
Tukey’s post hoc analyses were used for the pairwise 
difference for the dermal Tewameter values. The a 
priori significance level was P < 0.05. 
4. RESULTS 
4.1. The effects of the sub-acute oral 
administration from alkenones 
Statistical analysis indicated that the 
administration of 4000 mg/kg of the alkenones 
formulation did not significantly alter the body weight 
compared to animals treated with vehicle (Figure 2A). 
Furthermore, there was no significant difference in 
food consumption between the alkenones- and 
vehicle-treated animals Mann-Whitney analysis 
(Figure 2A). 
The oral administration of 4000 mg/kg of 
the alkenones formulation did not significantly alter 
behavior based on the facial grimace scale, the body 
postures or signs of stress compared to animals 
treated with the vehicle after 1-2-hour administration 
(data not shown). There was no significant difference 
in grip strength between both treated groups (data 
not shown). The gross necropsy results indicated that 
neither the administration of 4000 mg/kg of the 
alkenones formulation nor vehicle produced apparent 
signs of pathology (Figure 3). No histopathological 
changes were present in the liver, kidneys, spleen, 
heart, stomach, intestine and colon of animals 
treated with 4000 mg/kg of the alkenones or vehicle 
group (data not shown). The brain tissue was not 
evaluated as the alkenones, which consist of long 37 
hydrocarbon chain, would not cross the blood brain 
barrier intact. However, the metabolites of the 
alkenones could potentially cross the blood-brain 
barrier via fatty acid transport proteins (FATPs) (40). 
Further studies must be done to verify this 
hypothesis. 
The acute administration of the 4000 mg/kg 
formulation of the alkenones did not significantly alter 
the number of WBC, RBC, PLT, HGB, and 
monocytes or the level of haemoglobin (p < 0.05) 
compared to vehicle-treated animals (Figure 4). 
There was no significant difference between the 
alkenones- and vehicle-treated animals in the whole 
blood levels of albumin, total protein, globulin, Na+, 
K+, ALP, ALT, AMY, TBIL, BUN, CA, PHOS, CRE, 
and GLU (P < 0.05) (Figure 5). 
4.2. The effects of the sub-acute dermal 
exposure from alkenones 
We conducted experiments to determine 
the effects of topical administration of the either 1500 
mg/kg or 750 mg/kg of the alkenones formulation for 
24 hours to rats over 14 days. The body weights, as 
well as the food consumption, of the animals in Study 
1 and Study 2 were not significantly altered (P > 0.05 
for both measurements, Mann-Whitney U test) 
compare to animals treated with vehicle (Figure 6). 
Furthermore, the topical application of the alkenones 
 
 
Figure 2. Determination of (A) body weight, and (B) food 
consumption, following acute oral administration of alkenones (4000 
mg/kg) compared to vehicle in female SAS Sprague Dawley rats 
(n=6 per group). 
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did not significantly alter the relative weights of the 
liver, kidneys, spleen, heart, stomach, intestines and 
colon (data not shown). The exposure of skin to the 
positive control, 1% SLS, for 24 hours significantly 
increased (Sidak’s multiple comparison, P < 0.0001) 
skin water loss compared to the alkenones (1500 
mg/kg) and glycerin (Figure 7). The open cylinder 
chamber probe of the Tewameter® TM 300 was held 
against each skin with light pressure for at least 20 
seconds to get an average reading. TEWL values 
ranged from 0-10 (very healthy conditions) to above 
30, indicating critical skin conditions. If alkenones 
produce skin damage to the skin, then similar to the 
positive control, it should yield high TEWL values. 
Four out of ten rats had elevated TEWL readings 
compared to their positive controls, while all other 
topical application sites had TEWLs ranging from 0-
10 (i.e., very healthy skin condition) (Figure 7). 
4.3. The effects of repeated dermal 
exposure from alkenones 
The different repeated dermal treatment 
applications in Study 1 or Study 2 for 6 hour per day 
 
 
Figure 3. Histopathological evaluation of the (A) liver, (B) spleen, (C) heart, (D) kidney and (E) skin of SAS Sprague Dawley rat after acute 
oral exposure to vehicle control and alkenones (4000 mg/kg) after 14 days. (C1) Represents vehicle control rat 1, while (T1) represents treated 
rat 1. Treated samples were stained with haematoxylin and eosin (H&E) stains and observed at a magnification of 20× (n=6). There were no 
significant pathological changes in the various tissue sections between the vehicle and treated groups. 
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for 28 days did not significantly alter body weight 
(Mann-Whitney test) and food consumption (Mann-
Whitney test) between both study groups (Figure 6). 
Furthermore, the repeated dermal application of the 
alkenones did not significantly alter the relative 
weights for the liver, kidneys, spleen, heart, stomach, 
intestines and colon (data not shown). 
Following the 28-day exposure to the 
alkenones, the 1000 mg/kg dose of the alkenones 
only increased the TEWL value to 10 in one rat on 
day 1 of Study 1 (Figure 8). In addition, the 
application of saline (the negative control) also 
increased the TEWL in the aforementioned animal. 
The TEWL values for the positive control (1% SLS) 
were the highest on day 2, with eight out of ten rats 
having TEWL values greater than 10. Overall, the 
1000 mg/kg paste formulation of the alkenones 
significantly (Sidak’s multiple comparison, P 
< 0.0001) lowered the TEWL values throughout the 
28-day period compared to the positive control 
(Figure 9). The positive control always significantly 
increased water loss. 
5. DISCUSSION 
In order to determine how toxic alkenones 
are in case of accidental ingestion or exposure, sub-
acute oral toxicity was performed in animals. This is 
the first pilot toxicity study with the alkenones as there 
have been no previous published reports on the 
evaluation of alkenones toxicity in animals. Other 
studies have reported that Sprague-Dawley female 
rats have greater mechanical allodynia and 
sensitivity to oral toxicity (41, 42) compared to males. 
When determining the doses, we followed OECD 
Test No. 420 and 423 guidelines with modifications 
of starting with one animal at high dosage of 1000 
 
 
Figure 4. Blood chemistry profile to determine immune functions in SAS Sprague Dawley rats after acute oral exposure to vehicle control and 
alkenones (4000 mg/kg) for 14 days. The levels of (A) white blood cells (WBC), (B) platelets (PLT), (C) monocytes (D) red blood cells (RBC), 
and (E) haemoglobin (HGB) were measured from rats that were treated with vehicle or alkenones suspensions at the day 14. 
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mg/kg and observing the outcome. There are five 
toxicity categories with the class 1 being the most 
toxic at amounts up to 5 mg/kg. Compounds tested 
between 2000 mg/kg < LD50 ≤ 5000 mg/kg are 
labeled as a class 5 toxicity category, based on the 
criteria of the Globally Harmonized Hazard 
Classification and Labelling Scheme. This facilitates 
the identification of substances that produce toxicity 
at low doses (24). Although the class 5 toxicity 
category is optional, we included this category 
because the alkenones, if used to formulate personal 
care products or topical drugs, would come in contact 
with human skin. The rats treated with alkenones 
suspension solution produced no overt toxicity at 
4000 mg/kg given within 24 hours as compared to the 
vehicle suspension solution which lacked the 
alkenones. This high dosage was achieved by giving 
smaller dosages 1000 mg/kg every five hours to not 
overload the stomach capacity. Because daily 
exposure to the alkenones through oral gavage 
would have been stressful on the animals; we 
decided not to conduct chronic oral toxicity. If future 
requirements require chronic oral toxicity data, we 
will need to prepare the dosage of alkenones needs 
to be prepared in food pellets form so that the animals 
are exposed voluntarily and without stress. 
In this study, the alkenones derived from 
commercial Isochrysis algae were found to be in the 
class 5 toxicity category when given orally to SD 
female rats. The findings of our study indicate that 
alkenones have no acute toxicity under the present 
experimental conditions and its lowest lethal dose is 
above 4000 mg/kg in female SD rats. There was no 
significant change in food consumption for the 4000 
mg/kg alkenones group compared to the vehicle 
control group (Figure 2). During the acute oral 
observation study period, no deaths were recorded in 
either the control or the 4000 mg/kg group that was 
not due to accidental oral gavage injury or handling. 
 
 
Figure 5. Blood chemistry profile to determine organ toxicity in SAS Sprague Dawley rats after acute oral exposure to vehicle control and 
alkenones (4000 mg/kg) for 14 days. (A) Albumin, total protein, and globulin levels in grams per deciliter (g/dL), (B) alkaline phosphatase 
(ALP), alanine aminotransferase (ALT) and amylase (AMY) levels in units per liter (U/L), (C) sodium and potassium levels, millimoles per liter 
(mMol/L), (D) total bilirubin (TBIL), blood urea nitrogen (BUN), total calcium (CA), phosphorus (PHOS), creatinine (CRE) and glucose (GLU) 
levels in milligrams per deciliter (mg/dl) collected from rats treated acutely with oral vehicle and alkenones suspensions. 
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The observational behavioral data indicated that only 
grooming and partial eye closure occurred in the first 
10 minutes after treatment in both groups, which was 
considered to be a change attributable to the 
handling or oral gavage administration. There were 
no significant changes in the 1) grip strength between 
both groups and 2) behavioral or physical parameters 
during the 14-day study. 
The oral administration of 4000 mg/kg 
alkenones suspensions did not induce abnormalities 
in the gross necropsy after 14-days of observation 
and did not significantly alter the weight of the organs 
compared the vehicle control group. The histology 
data showed no significant changes in the 
alkenones-treated group compared to the vehicle 
control group. Thus, even at a high dose, alkenones 
did not induce any organ-specific damage. The blood 
analysis results indicated a slight, non-significant 
decrease in monocytes in the animals treated with 
4000 mg/kg alkenones compared to vehicle-treated 
animals. However, there was no significant difference 
between the alkenones and vehicle-treated animals 
in the number of WBC, RBC, PLT or HGB levels or 
the 14 biochemical parameters tested. 
Polysaccharides from the Iscochrysis sp. can 
produce immunomodulatory effects by increasing the 
levels of IL-1β in macrophages and monocytes (43) 
which might suggest why the level of monocytes 
changed with alkenone treated rats. Currently, the 
explanation for this difference is unknown. Overall, 
our results suggest that the acute oral administration 
of alkenones (4000 mg/kg) did not alter the blood 
chemistry or damage major organs under the 
experimental conditions used. 
Dermal acute and sub-chronic exposures 
studies were performed to determine alkenones 
effect on direct exposure to the skin in animals. When 
determining the fixed doses, we followed OECD Test 
No. 434 guidelines with modifications for the use of 
five animals at 1500 mg/kg in Study 1, the highest 
 
 
Figure 6. Determination of (A) body weight, and (C) food consumption, following acute dermal exposure of Study 1 compared to Study 2 in 
female SAS Sprague Dawley rats (n=5). Determination of (B) body weight, and (D) food consumption, following repeated dermal exposure of 
Study 1 compared to Study 2 in female SAS Sprague Dawley rats (n=5). 
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Figure 7. The trans-epidermal water loss (TEWL) was measured before and 24 hours after acute dermal application in (A) Study 1 group 
treated with 1% SLS (positive control), saline (negative control), glycerin (vehicle) and 1500 mg/kg alkenones (AK); (B) Study 2 group treated 
1% SLS (positive control), vehicle (glycerin), 750 mg/kg and 1500 mg/kg alkenones (AK); (C) Combined data from Study 1 and 2 to show any 
significant change in TEWL measurements. (D) The trans-epidermal water loss (TEWL) was measured before and after acute application of 
1% SLS (sodium lauryl sulphate), alkenones (1500 mg/kg) and vehicle (glycerin) on dermal skin in SAS Sprague Dawley rats. Two-way ANOVA 
analysis followed by Tukey’s multiple comparisons tests indicated the changes between baseline and 24 hours TEWL readings. 
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dose used. A second dose of 750 mg/kg was also 
included in Study 2 animals in case they were effects 
with a different amount of alkenones and the vehicle 
used as well as to find any effects with a larger skin 
surface area of alkenones exposed directly to the 
skin. The Draize skin irritation numerical scale was 
used to record the degree of skin damage for each 
site. The 1500 mg/kg and the 750 mg/kg doses of the 
alkenones did not produce erythema, eschar, or 
edema formation during the 24 hours of contact at the 
skin sites. Thus, Study 2 rats in the acute dermal test 
were able to tolerate the alkenones on a large surface 
area of the skin and the different amounts of 
alkenones with the vehicle showed no change in 
effects at a single treatment. The Draize skin reaction 
numerical scale showed no redness at the other 
treatment sites when compared to the positive 
control. It was noted that scabs from the positive skin 
site application lasted only four days’ post-treatment 
in some sensitive SD rats. For the sub-chronic 
repeated treatments, the Study 2 rats exposed to 
1000 mg/kg, 200 mg/kg, and 50 mg/kg alkenones did 
not have erythema, eschar, or edema during the 6 
hours of contact per day on the skin sites. There was 
an increase in the irritation score only on Day 25, as 
indicated by the reddening of the skin at the 1000 
 
 
Figure 8. The trans-epidermal water loss (TEWL) was measured before and after 6 hours repeated dermal exposure every day for 28 days 
on skin area exposed to (A) 1% SLS (positive control), (B) 200 mg/kg alkenones, (C) normal saline (negative control), (D) 1000 mg/kg 
alkenones, (E) 50 mg/kg alkenones and (F) glycerin. The rats were divided into two groups. Rats 11, 12, 15, 16, and 19 were treated with 1% 
SLS, 50 mg/kg alkenones, 200 mg/kg alkenones, and 1000 mg/kg alkenones). Rats 13, 14, 17, 18, and 20 were treated with 1% SLS, saline, 
glycerin (vehicle) and 1000 mg/kg alkenones. 
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mg/kg dose of the alkenones, but this score was 
lower than that of the positive control, whose values 
were higher than all of the other treatments. The 
positive control, 1% SLS, did produce erythema and 
eschar formation on the skin in four, but not all rats. 
In either Study 1 or 2 animals the application of the 
1000 mg/kg alkenones formulation for 6 hours per 
day for 28 days did not produce erythema, edema, or 
eschar formation during the first two weeks. The 
positive control produced greater water evaporation 
after 6 hours. During the third and fourth week, 
erythema was present in certain rats of Study 2 after 
1000 mg/kg of the alkenones formulation was applied 
on the skin. However, erythema was seen after the 
application of both the negative control and vehicle, 
possibly as a result of the bandage being too tight on 
a specific day. From both experiments, alkenones did 
not produce a noticeable severe dermal irritation 
 
 
Figure 9. The trans-epidermal water loss (TEWL) measurements before and after 6 hours repeated dermal exposure of different treatments 
each day at (A) Day 1, (D) Day 2, (B) Day 8, (E) Day 14, (C) Day 21, and (F) Day 28. 
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when placed on the skin for a single 24 hours contact 
or repeated 6 hours contacts for a 28 day period. 
The Tewameter device was used as a 
secondary confirmation of skin damage due to water 
loss. TEWL can be produced by environmental 
stressors such as ultraviolet radiation, which 
damages the skin by producing reactive oxygen 
species (44). In the acute dermal study, there was no 
significant difference in the TEWL values between 
the alkenones- and vehicle-treated animals. The 
Tewameter data indicated that only the positive 
control, 1% SLS, significantly increased water 
evaporation before and after 24 hours of treatment 
(Figure 7). Alkenones applied to the skin sub-chronic 
28-day repeated treatment did not produce 
significant skin damage compared to the positive 
control, based on TEWL readings taken both before 
and after the 6-hour daily applications. The 
alkenones tested did not significantly increase water 
loss in either single or repeated dermal exposure.
One limitation of this study was that we only 
used SD rats. These alkenones could be used in 
human epidermis models such as EpiSkin or 
EpiDerm to further evaluate their effects on the 
morphology of the skin cells and testing for 
phototoxicity and corrosivity (45). A second limitation 
was the alkenones could not be evaluated in vitro due 
to issues with their solubility. The alkenones would 
either precipitate out of DMSO, DMEM medium, 
Tween 20, Tween 80, and sesame seed oil, or the 
solution became cloudy and opaque after sonication 
for 15 seconds. Consequently, we could only conduct 
in vivo studies with the alkenones using a suspension 
formulation. The solvent dichloromethane completely 
dissolves the alkenones, but dichloromethane is 
extremely toxic in cell lines and animals (46). Another 
limitation was the delivery of the alkenones to the rats 
through oral gavage. The delivery via water was not 
feasible as the alkenones are insoluble in water. A 
suspension of alkenones greater than 200 w/v % was 
too viscous to pass through the stainless-steel 
gavage needle. Therefore, a suspension of 100 w/v 
% was given to the rats four times within a 24-hour 
period. While corn oil was an option, when mixed with 
the alkenones, it took a longer time to pass through 
the needle with more force than should be required 
to deliver the solution into the stomach. We 
subsequently used a suspension solution, as 
suggested by Turner (29), to decrease the stress to 
the animals. 
Glycerin is a common ingredient used in 
drug formulation and personal care products (47). In 
addition, it is important to note that glycerin is a 
humectant which attracts and keeps moisture to the 
site of application (48). Although it is safe for skin use, 
it may have some effects of irritating properties when 
different amount of the alkenones are mixed. 
Following the application of a high concentration of 
the alkenones (more than what may be present in a 
typical skin care product), a large amount of the 
alkenones were left on the skin site application after 
6 (1000 mg/kg) and 24 hours (1500 mg/kg). 
Interestingly, even when alkenones were applied at a 
larger surface area of the skin, the treatments were 
well tolerated with overall no change between the 
different concentrations of alkenones and vehicle 
mixtures. Nonetheless, our toxicity study provided 
new information regarding how well the skin in female 
SD rats could tolerate alkenones for extended 
periods of time. 
In conclusion, the toxicity studies indicated 
that the alkenones could be classified as level 5 LD50 
toxicant according to globally harmonized hazard 
classification and labelling scheme (GHS). Our 
results indicated the alkenones from Isochrysis sp. 
were practically non-toxic. They were determined to 
be safe after acute oral and or dermal exposure for 
up to 28 days in rats in this study. Based on this 
study, we presume that animals or humans exposed 
to alkenones should not experience any significant 
adverse effects. As mentioned previously, Isochrysis 
sp. has been grown as animal feed for both farm (49) 
and marine animals (50). Other nutrient ingredients 
sought after from Isochrysis sp. are 
eicosapentaenoic acid, an omega-3 fatty acid, (18) 
and docosahexaenoic acid, another omega-3 fatty 
acid that is the primary structural component of the 
human brain and retina (51) Using alkenones derived 
from the commercially available Isochrysis sp. algae 
in drug/personal care formulations productions may 
represent another promising source for 
pharmaceutical companies. Also, in a previous study 
(16), the same alkenones tested for toxicity had a low 
SolS value and high ISG values, indicating the 
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alkenones alone were less compatible with the 
stratum corneum and thus less likely to penetrate the 
skin. Although the Federal Food, Drug, and Cosmetic 
Act (FFDCA) do not require excipient ingredients to 
be approved by the United States Food and Drug 
Administration (FDA) before they are marketed, the 
ingredients must be safe for consumers under the 
labeled conditions of use. A follow-up study with 
clinical trials using alkenones should be assessed in 
healthy volunteers to confirm two things. First, that no 
other toxic effects are seen that differ from the animal 
studies. Second, to confirm the safety of using 
alkenones in human application products. Once the 
correct formulation for use has been determined, 
alkenones may prove to be a useful ingredient in 
products from personal care companies that are 
constantly searching for natural, green, sustainable 
ingredients. 
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